Onconova Therapeutics Inc. (NASDAQ:ONTX) has a beta value of 1.6 and has seen 5,788,902 shares traded in the last trading session. The company, currently valued at $170.24 Million, closed the last trade at $0.72 per share which meant it lost -$0.01 on the day or -1.03% during that session. The ONTX stock price is -168.06% off its 52-week high price of $1.93 and 73.61% above the 52-week low of $0.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.68 Million shares traded. The 3-month trading volume is 42.64 Million shares.
The consensus among analysts is that Onconova Therapeutics Inc. (ONTX) is an Overweight stock at the moment, with a recommendation rating of 2.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.03.
Onconova Therapeutics Inc. (NASDAQ:ONTX) trade information
Despite being -1.03% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the ONTX stock price touched $0.8099 or saw a rise of 11.16%. Year-to-date, Onconova Therapeutics Inc. shares have moved 54.47%, while the 5-day performance has seen it change -2.91%. Over the past 30 days, the shares of Onconova Therapeutics Inc. (NASDAQ:ONTX) have changed -26.59%. Short interest in the company has seen 6.02 Million shares shorted with days to cover at 0.14.
Wall Street analysts have a consensus price target for the stock at $2.1, which means that the shares’ value could jump 191.67% from current levels. The projected low price target is $2.1 while the price target rests at a high of $2.1. In that case, then, we find that the current price level is +191.67% off the targeted high while a plunge would see the stock lose 191.67% from current levels.
Onconova Therapeutics Inc. (ONTX) estimates and forecasts
1 analysts offering their estimates for the company have set an average revenue estimate of $60Million for the current quarter. 1 have an estimated revenue figure of $60Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $150Million and $56Million respectively for this quarter and the next, and analysts expect sales will grow by -60% for the current quarter and 7.1% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +75.3% over the past 5 years. Earnings growth for 2021 is a modest +90.3%.
Onconova Therapeutics Inc. (NASDAQ:ONTX)’s Major holders
Insiders own 0.53% of the company shares, while shares held by institutions stand at 15.08% with a share float percentage of 15.16%. Investors are also buoyed by the number of investors in a company, with Onconova Therapeutics Inc. having a total of 44 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc. (The) with over 8.26 Million shares worth more than $3.85 Million. As of December 30, 2020, Vanguard Group Inc. (The) held 3.49% of shares outstanding.
The other major institutional holder is Geode Capital Management, LLC, with the holding of over 1.29 Million shares as of December 30, 2020. The firm’s total holdings are worth over $600.05 Thousand and represent 0.54% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of December 30, 2020, the former fund manager holds about 2.47% shares in the company for having 5849848 shares of worth $2.72 Million while later fund manager owns 2.15 Million shares of worth $999.22 Thousand as of December 30, 2020, which makes it owner of about 0.91% of company’s outstanding stock.